Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

In a week that’s seen Joe Abercrombie deliver his best sales to date, the author finds his latest offering The Devils ...

Exelixis, Inc. EXEL reported better-than-expected first-quarter 2025 results. EXEL recorded adjusted earnings of 62 cents per ...